



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_169_25

You asked:

I am writing to request information under the Freedom of Information Act 2000 in England and Wales and Freedom of Information Act 2002 (Scotland). I would like to request data on the treatment of patients with hormone therapies for prostate cancer at your Trust for the period January 1, 2023- December 31, 2024. Specifically, I am seeking the following information:

Request for Information

For each of the following hormone therapies used to treat prostate cancer, please provide the number of patients treated at your Trust between 01 January and 31 December (by years 2023 and 2024). For each therapy, broken down the data into the following categories:

1. Total Number of Patients Treated for ICD-10 C61 / M1-M1c (metastatic)
2. Number of Patients for Whom Hormone Therapy Was Initiated for ICD-10 C61 / M1-M1c (metastatic)
3. Number of Patients for Whom Hormone Therapy Was Continued; ICD-10 C61 / M1-M1c (metastatic)
4. Number of patients for whom docetaxel was initiated for ICD-10 C61 / M1-M1c (localised & metastatic)

The hormone therapies of interest are:

- a) ADT alone
- b) Abiraterone (Zytiga) in combination with any ADT
- c) Abiraterone (Zytiga) – no ADT
- d) Enzalutamide (Xtandi) in combination with any ADT
- e) Enzalutamide (Xtandi) – no ADT
- f) Apalutamide (Erleada) in combination with any ADT
- g) Darolutamide (Nubeqa) in combination with any ADT
- h) Darolutamide (Nubeqa) in combination with any ADT with docetaxel
- i) Docetaxel in combination with any ADT

Total number of patients in each year, for each therapy for whom:

- Hormone therapy was initiated
- Hormone therapy was continued
- Docetaxel was initiated

If any part of this information is not available or cannot be provided, please provide whatever information you are able to. I would appreciate it if you could provide the information in an electronic format, preferably in the **attached spreadsheet format**.

Our response:

We can confirm that Cwm Taf Morgannwg University Health Board does not hold the information you require. Cwm Taf Morgannwg residents receive prostate

cancer treatments from the Velindre Cancer Centre. Therefore, you will need to redirect your request to Velindre, who provide these services to Cwm Taf Morgannwg residents.

Contact details are shown below in the following links:

For Velindre:

[Freedom of information contacts - Velindre University NHS Trust](#)